摘要
人干扰素α1b是我国首个基因工程Ⅰ类新药,已获批应用于黑色素瘤等多种肿瘤的治疗.人干扰素α1b作为黑色素瘤术后辅助治疗及晚期系统治疗药物,可有效改善黑色素瘤患者生存且安全性好.中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组及中国抗癌协会黑色素瘤专业委员会组织本领域专家,结合临床应用经验并参考新近文献,制订本共识,以期为黑色素瘤临床治疗决策提供参考.
Human interferon α1b is the first genetically engineered classⅠdrug in China,and has been approved for the treatment of melanoma and other tumors.As an adjuvant treatment for resected melanoma and a systemic treatment for advanced melanoma,human interferonα1b can effectively improve the survival of patients while maintaining a favorable safety profile.Based on clinical application experience and recent literature,the Skin Cancer Research Group,Committee on Dermatology,Chinese Association of Integrative Medicine and Melanoma Society of China Anti-Cancer Association convened experts in this field to develop this consensus,aiming to provide a reference for clinical treatment decisions regarding melanoma.
出处
《中华皮肤科杂志》
CSCD
北大核心
2024年第1期1-7,共7页
Chinese Journal of Dermatology
关键词
黑色素瘤
干扰素Α
肿瘤治疗方案
术后辅助治疗
人干扰素α1b
系统治疗
专家共识
Melanoma
Interferon-alpha
Antineoplastic protocols
Postoperative adjuvant therapy
Human interferon α1b
Systemic therapy
Expert consensus
